Such a group was studied in REDUCE-IT. This trial involved 8,179 patients with CVD or diabetes plus other risk factors and LDL levels of 40-100 mg/dL on statin therapy. Over five years, 4 grams a day of the fish oil icosapent ethyl reduced both first and subsequent heart attacks and strokes as well as CVD deaths by 25%. Although icosapent ethyl is a TG-lowering agent, the results appeared to be independent of patients' baseline TG levels. This suggests some benefit was due to independent actions, such as potent plaque-stabilizing properties. This fish oil product is currently FDA-approved only for treating TG levels above 500 mg/dL.